The Clinical Core will provide assistance in patient enrollment and follov /-up, data management (data collection, computer data entry), data analyses (reports), and biostatistical support (study design, statistical analyses) for grant investigators. The Clinical Core will have two basic responsibilities: 1) the extraction and inputting of data into the multicenter database, including clinical data from the study sites and genotyping results from the Genotyping Core. This will also include maintenance ofthe database, quality control of the data, sample tracking and assurance of HIPPA compliance. 2) The second responsibility will be to provide statistical support to the two projects, including reports for Projects 1 and 2. We have well-established, quality procedures for data transmission, entry into our multicenter database, and protection ofthe confidentiality of information of patients. To date, we have enrolled 1010 donors and 2864 recipients in our genomic grant (and expect enrollment as of 8/1/11 to be about 1280 donors and 3500 recipients) and have collected samples for genotyping. With continued enrollment of about 800 recipients per year, we anticipate that our data analyses will include information on over 6000 recipients and 2300 living donors. Our plan for data management and specimen storage is to build upon the system we have used successfully for this study and in previous studies within the Division of Biostatistics. Our data management system is comprehensive, mature and fully developed and is being used now very successfully in several national and international studies. It is a cost-effective, efficient approach. The Core has the required expertise (including expertise in bioinformatics), and facilities for the analyses of the SNP data and the studies of associations of SNPs with our endpoints. Because data will be collected and entered into a database that will be used for both projects, the project investigators can focus on the unique aspects of their individual studies.

Public Health Relevance

; The Clinical Core is essential to our goals: to determine if genetic variation is associated with kidney transplant outcome and /or immunosuppressive drug disposition and toxicity. Both projects will use Core services. Both projects rely on the Core for data collection and management, quality control, and biostatistical support. The Core provides the expertise of a biostatistical group composed of statistical geneticists and analysts specialized in bioinformatics analytical techniques.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI070119-06
Application #
8224747
Study Section
Special Emphasis Panel (ZAI1-MFH-I (M2))
Project Start
2011-08-01
Project End
2016-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
6
Fiscal Year
2011
Total Cost
$124,026
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Wu, Jennifer F; Muthusamy, Amutha; Al-Ghalith, Gabriel A et al. (2018) Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients. Clin Transplant 32:e13436
Scheibner, Aileen; Remmel, Rory; Schladt, David et al. (2018) Tacrolimus Elimination in Four Patients With a CYP3A5*3/*3 CYP3A4*22/*22 Genotype Combination. Pharmacotherapy :
Seibert, Stephan R; Schladt, David P; Wu, Baolin et al. (2018) Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 32:e13424
Snoek, Rozemarijn; van Setten, Jessica; Keating, Brendan J et al. (2018) NPHP1 (Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD. J Am Soc Nephrol 29:1772-1779
Oetting, William S; Wu, Baolin; Schladt, David P et al. (2018) Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics 19:175-184
Okour, Malek; Jacobson, Pamala A; Ahmed, Mariam A et al. (2018) Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure. J Clin Pharmacol 58:628-639
Dorr, Casey R; Wu, Baolin; Remmel, Rory P et al. (2018) Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing. Pharmacogenomics J :
Dorr, Casey R; Oetting, William S; Jacobson, Pamala A et al. (2018) Genetics of acute rejection after kidney transplantation. Transpl Int 31:263-277
Dorr, Casey R; Remmel, Rory P; Muthusamy, Amutha et al. (2017) CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism. Drug Metab Dispos 45:957-965
Sanghavi, K; Brundage, R C; Miller, M B et al. (2017) Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J 17:61-68

Showing the most recent 10 out of 44 publications